Beta Drugs Ltd. Announces 21st AGM on Sep 30, 2026; To Discuss Financials, Director Re-appointments
Beta Drugs Limited will hold its 21st AGM on September 30, 2026. The meeting will focus on adopting financial statements for FY26 and re-appointing directors Mr. Ajay Mahipal and Mr. Ashutosh Shukla. Statutory Auditors M/s Khurana Sharma & Co. are proposed for re-appointment for two years. Mr. Ashutosh Shukla's re-appointment as Whole-time Director for five years from Jan 2027 is also on the agenda.
The AGM agenda includes critical decisions regarding director re-appointments, auditor appointments, and financial statement approvals, which are important for corporate governance and operational continuity. The re-appointment of directors and auditors has a direct impact on the company's leadership and compliance.
The announcement is a routine notice for the Annual General Meeting, detailing standard corporate procedures like financial statement adoption and director re-appointments. It does not contain any new financial performance data or strategic shifts that would indicate a positive or negative sentiment.
Beta Drugs Limited has announced its 21st Annual General Meeting (AGM) will be held on Wednesday, September 30, 2026, at 10:30 a.m. at the company's registered office in Baddi, Himachal Pradesh.
The primary agenda for the AGM includes the adoption of audited standalone and consolidated financial statements for the year ended March 31, 2026. Shareholders will also vote on the re-appointment of two directors, Mr. Ajay Mahipal and Mr. Ashutosh Shukla, who are retiring by rotation and seeking re-election.
Further business to be transacted includes the re-appointment of M/s Khurana Sharma & Co. as the Statutory Auditors for a second term of two years, with their remuneration fixed at ₹4,20,000 per annum plus applicable taxes and expenses. The shareholders will also ratify the remuneration of M/s Charu Jindal & Co. as the Cost Auditor for the financial year 2026-27, set at ₹1,25,000 with reimbursement of expenses and applicable GST.
Additionally, the AGM will seek shareholder approval for the re-appointment of Mr. Ashutosh Shukla as Whole-time Director for a period of five years from January 20, 2027, to January 19, 2032. His monthly remuneration is proposed to be ₹3,94,419, plus Diwali bonus and incentives, with a provision for revision and a cap of ₹10 lacs per month. The Register of Members and Share Transfer Books will remain closed from September 24, 2026, to September 30, 2026, inclusive, for the AGM.
What to do with a filing like this
Beta Drugs Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Beta Drugs Limited. Read the original for the full detail.